Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA plus decitabine vs decitabine in newly diagnosed higher-risk MDS with high RARA expression
ChiCTR2600122973Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing ATRA + decitabine with Placebo + decitabine (2 arms). Primary endpoints: Overall survival, Duration of response and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
tretinoindecitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600122973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122973.